Stem cell research: cutting-edge science or corporate subsidies, courtesy of voters?
By Capitol Weekly,
Capitol Weekly
| 09. 15. 2005
[Quotes CGS's Marcy Darnovsky]
The organizations created to fund stem cell research in California announced
their first grants last week, despite the fact that the money is held up in
lawsuits. But are they rushing to further science or escape politics?
Last fall, voters approved a stem cell initiative, Proposition 71, by a
59-41 percent margin. Ten months later, the $3 billion in bonds voters
approved are tied up in lawsuits by Republican and anti-abortion groups who
oppose embryonic stem cell research.
Yet, in the long-run, the organizations created by Prop. 71--the Independent
Citizen_s Oversight Committee and the California Institute for Regenerative
Medicine--may have more to worry about from their original allies. A
coalition of Democratic skeptics has put forth a message more likely to gain
traction: You can support stem cell research and still oppose the results of
Prop. 71.
"The debate was framed as being a referendum on stem cell research and
whether you support President Bush," said Jesse Reynolds of the Center for
Genetics and Society. "California voters didn_t approve this as a corporate
subsidy."
Reynolds_ message has gotten support in...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...